Favipiravir was canceled

Japanese scientists have declared the ineffectiveness of Favipiravir in the treatment of coronavirus

<url> 

Clinical trials of the flu drug Favipiravir, which is also known as Avigan, which took place in Japan, have shown its ineffectiveness in the treatment of coronavirus, Kyodo news agency reports.

Studies have shown that in those patients who took Favipiravir and those who did not use it, there is no visible difference in the results of treatment of coronavirus.

"Favipiravir" was developed by the Japanese corporation Fujifilm Holdings. The drug has shown effectiveness against life-threatening Ebola and Lassa fever viruses, rabies viruses.

In 2014, Favipiravir was approved in Japan as a drug against some forms of influenza. Due to the side effects associated with the effect of the drug on the DNA of the unborn child with the risk of fetal damage, the drug has never been sold openly on the market, but the Japanese government keeps its stock in case of an epidemic of influenza.

On March 17, 2020, one of the largest pharmaceutical companies in China, Zhejiang Hisun Pharmaceutical, received permission from the authorities to start selling Favipiravir as a potential drug for coronavirus infection. The Ministry of Science and Technology of China then said that the drug has "relatively obvious effectiveness."

On May 30, Favipiravir, manufactured in Russia under the trade name Avifavir, was registered as a medicine for coronavirus infection. It is not intended for retail sale, and is allowed for use only in a hospital setting.

Portal "Eternal youth" http://vechnayamolodost.ru